INTRODUCTION:

Oxaliplatin, a third-generation platinum compound, one of the mainstay drugs in the treatment of many gastrointestinal cancers, can give rise to hypersensitivity reactions, sometimes with fatal outcomes. It is usually combined with 5-fluorouracil (5-FU), capecitabine, irinotecan, or cyclophosphamide. It is a non-cell cycle specific alkylating agent that causes abnormal crosslinking or cutting of DNA strands and eventually leading to cell death.

Hypersensitivity reactions to platinum containing compounds are well described and potentially life-threatening. The hypersensitivity reactions can occur either during or shortly after the infusion of drug. The incidence increases with increase in the number of chemotherapy cycles. Hypersensitivity reactions can vary from mild reactions like rashes to severe reactions, which include laryngospasm, tachycardia, hypotension or hypertension. The combination of 5-fluorouracil, leucovorin and oxaliplatin has been used in several studies to increase survival rates and reduce the risk of disease progression in patients with metastatic colorectal cancer (CRC) and stage III colon cancer. We report a case of a patient treated with oxaliplatin who developed Severe Grade-III Toxicity including Hypoxemia, Chills and Hypersensitivity Reaction like rashes all over the body and itching sensation about few hrs after the oxaliplatin infusion. Patient tolerated 7 cycles of FLOT chemotherapy well. During cycle 8 chemotherapy after 50% infusion of oxaliplatin patient developed severe reaction to oxaliplatin such as breathlessness, shivering, hypersensitivity reaction like rashes all over the body and itching sensation. The drug infusion was stopped immediately, vitals were checked which shows BP: 170/110mmHg, Temperature 100°F, SpO2 85% RA. It was confirmed as grade 3 toxicity of oxaliplatin. The adverse drug reaction assessment was done using Naranjo’s causality assessment scale which showed ‘definite’ type of adverse drug reaction with oxaliplatin. Prompt recognition of this event and symptomatic treatment with supplemental oxygen and corticosteroids and prolonging the infusion time of oxaliplatin can lead to better patient compliance and lesser hypersensitivity reactions to these regimens.

Keywords: Oxaliplatin, Colorectal cancer (CRC), Dyspnoea, Hypersensitivity reactions, Chemotherapy.

Hypersensitivity reactions to platinum containing compounds are well described and potentially life threatening. The hypersensitivity reactions can occur either during or shortly after the infusion of drug. The incidence increases with increase in the number of chemotherapy cycles. Hypersensitivity reactions can vary from mild reactions like rashes to severe reactions, which include laryngospasm, tachycardia, hypotension or hypertension.

Oxaliplatin is less nephrotoxic than cisplatin and less myelotoxic than carboplatin. The most characteristic and dose limiting toxicity of oxaliplatin is sensory neuropathy, transient acute cold related dysesthesias, sometimes pain associated although it is generally reversible. Hypersensitivity reactions to oxaliplatin have been described as anaphylaxis. This reaction is clinically characterised by laryngospasm and wheezing and immunologically linked to the release of histamine and other vasoactive substances.

Oxaliplatin has been widely used in patients with gastrointestinal malignancies including colorectal cancer (CRC).
The combination of 5-fluorouracil, leucovarin and oxaliplatin (FOLFOX) has been used in several studies to increase survival rates and reduce the risk of disease progression in patients with metastatic CRC and stage III colon cancer.

Hypersensitivity is a possible adverse effect of exposure to platinum compounds and the incidence increases with multiple cycles of therapy. The hypersensitivity reaction associated with oxaliplatin typically consists of rigors, fever, rashes, tachycardia, and dyspnea. The incidence in patients with CRC was reported as high as 15% and mainly occurred shortly after infusion in patients who had prior exposure to oxaliplatin.

The mild hypersensitivity reaction (grade 1 and 2) usually responds to discontinuation of oxaliplatin and supportive treatment with antihistamine agents and steroid. Frequently, patients with mild hypersensitivity reaction can be retreated with oxaliplatin by adding appropriate premedications such as antihistamine agents and steroids and increasing infusion time with more diluted concentration.

Severe and potentially fatal hypersensitivity reaction with symptoms of bronchospasm, angioedema, hypotension and anaphylaxis occurred on 2% patients receiving oxaliplatin treatment. Although the manufacturer recommends not to re-treat with oxaliplatin after the incidence of severe hypersensitivity reaction, a desensitization protocol has been successfully implemented in patients with grade 3 hypersensitivity reaction.

Here, we report a case of a patient treated with oxaliplatin who developed Severe Grade-III Toxicity including Hypoxemia, Chills and hypersensitivity reaction like rashes all over the body with itching sensation about few hrs after the oxaliplatin infusion during 8th cycle of FLOT Chemotherapy.

**CASE REPORT:**

A 54-year-old male patient was presented with epigastric pain and early satiety in the past 6 months. He was diagnosed as gastric carcinoma stage III PT3N3bM0. Endoscopy revealed presence of ulcerative growth in the stomach. Biopsy from the lesion showed presence of moderately differentiated adenocarcinoma, diffuse type, poorly differentiated. Tumour located in body, pylorus and antrum. Tumour measures 7 cm in dimensions, tumour invades subserosal fat and reaches up to serosal margin. Lymphovascular invasion is identified. Proximal and distal margins are free of tumour. 29 out of 48 lymphnodes show metastatic tumour deposit, size of large deposit measures 1cm in greatest dimensions with extranodal extension.

He underwent laproscopy of distal gastrectomy + jejunojenostomy + feeding jejunostomy + splenectomy on 10/3/2020.laboratory tests for chest X-ray PA view, CBP, blood for culture and sensitivity, HIV 1 and 2, USG whole abdomen were within normal limits. Multislice spiral CT whole abdomen revealed focal circumferential wall thickening in distal part of body of stomach and gastric antrum showing significant enhancement and multiple perilestonal lymphnodes and fat stranding S/O malignant gastric wall thickening. UGI scan revealed proliferative mass in lesser curvature, indicating stomach cancer. Histopathology report of surgical specimen revealed adenocarcinoma poorly differentiated PT3N3bM0, lymphovascular invasion present, perinodal extension present. He was planned for adjuvant chemotherapy with FLOT regimen. Completed cycle 7 chemotherapy and was asked to review after 21st day for cycle 8 FLOT regimen.

Chemotherapeutic drugs for FLOT regimen include Inj. 5-fluorouracil 300mg in Baxter pump approximately for 48 hrs, Inj. Docetaxel 60 mg in 500ml normal saline ~2 ½ hours, Inj. leucovorin 270 mg in 100ml normal saline ~ 1 hour, and Inj. oxaliplatin 110mg in 500ml 5% dextrose ~ 2 ½ hours.

Patient tolerated 7 cycles of chemotherapy well. During cycle 8 chemotherapy after 50% infusion of oxaliplatin patient developed severe reaction to oxaliplatin such as breathlessness, shivering, hypersensitivity reaction like rashes all over the body and itching sensation. The drug infusion was stopped immediately, vitals were checked which shows BP: 170/110mmhg, Temperature 100°F, SpO2 85% RA. It was confirmed as grade 3 toxicity of oxaliplatin. He was prescribed with Inj. Hydrocort stat, Inj. Avil 1 Amp stat, Inj. Paracetamol 1gm IV stat were given. Continuous vital monitoring was done. When symptoms were improved and vitals were stable (nearly after 30 to 45 min), infusion was restarted with dose reduction rate. Within 5 min of infusion patient again developed itching and rashes on hands. Infusion was stopped and discarded. Patient was kept 1 day for observation and then got discharged in stable condition.

The adverse drug reaction assessment was done using Naranjo's causality assessment scale which showed 'definite' type of adverse drug reaction with oxaliplatin. The patient was asked to review after 1 month for re-evaluation with CBP, serum creatinine and serum bilirubin.

**DISCUSSION:**

Hypersensitivity to platinum derivatives was first reported in 2004. A second report of delayed oxaliplatin induced laryngeal spasm was reported in 2009. Another report showing ADR developed 24 hours after the 1st and 2nd dose infusion of oxaliplatin.

Oxaliplatin a coordination compound of DACH carrier group showing ADR developed 24 hours after the 1st and 2nd dose infusion of oxaliplatin. Oxaliplatin a coordination compound of DACH carrier group and an oxalate leaving group was active in cisplatin response models. Like cisplatin oxalate preferentially forms adducts at N7 position of guanine and to lesser extent adenine however there is evidence that the 3-dimensional structure of DNA adducts and biologic response they elicit are different from those of cisplatin.

In the immediate onset cases, the patient showed various symptoms. In previous reports; approximately 40% of allergic patients showed rash or cutaneous reactions. In our case the patient had breathlessness, shivering, hypersensitivity reaction like rashes all over the body and itching sensation which was treated with Inj. Hydrocort stat, and Inj. Avil 1 ampule stat. Hypertension and dyspnea were severe complaints, and in our case, patient had a reaction of grade 3 Toxicity.

In a case study conducted by Siu et al five patients with grade 3 severity required oxygen. Siu et al (10) found rates of 14.8% for dyspnea and 7.4% for hypotension in patients with hypersensitivity to oxaliplatin. These results suggest that respiratory problems due to oxaliplatin allergy may be more severe than initially apparent, and a saturation monitor should always be used in cases of immediate onset allergy.

According to a MEDLINE search for recent and past studies, case reports, metaanalysis and review pertaining to oxaliplatin related hypersensitivity reactions are performed, the mechanism for oxaliplatin induced hypersensitivity reaction...
reaction is associated with immunoglobulins Ig-E mediated hypersensitivity 19.

The hypersensitivity reactions can be minimised by increasing the infusion time from two to six hours. Administration of intravenous calcium gluconate and magnesium sulphate, 1 g each, just before the oxaliplatin infusion is reported to decrease the incidence of acute neurotoxicity as well as laryngospasm especially pseudo laryngospasm. 20

Re-introduction of therapy was tried to this patient and he showed relapse of allergy. Therefore, re-introduction of therapy requires premedication with steroids and histamine receptor antagonists, and patients should be monitored closely for relapse of allergy. The adverse drug reaction was assessed by using Naranjo's Causality Assessment Scale which showed definite type of reaction with oxaliplatin.

Our study aims to contribute awareness about the adverse drug reaction related to oxaliplatin. As oxaliplatin is approved for the treatment of advanced colorectal cancer and enhances cure rate in adjuvant set. The therapeutic role of oxaliplatin has been found to extend to pancreatic gastric and oesophageal cancer. Close monitoring is required while infusing oxaliplatin for prompt identification and management of oxaliplatin induced hypersensitivity reaction, which may occur after many hours of oxaliplatin infusion. Overall, our case suggests that oxaliplatin allergy is an important concern and that methods for suppression of allergic response is required.

**CONCLUSION:**

This case report suggests that oxaliplatin has a propensity to cause severe hypersensitivity reactions manifesting as Hypoxemia and chills with subsequent doses of infusion and not with a single dose. As use of this agent becomes more widespread, increased vigilance for this potential serious complication should be high. Previous exposure to oxaliplatin is a risk factor for earlier Hypersensitivity Reaction onset and more severe and frequent Hypersensitivity Reaction episodes, even if prior therapy was well tolerated. Prompt recognition of this event and symptomatic treatment with supplemental oxygen and corticosteroids and prolonging the infusion time of oxaliplatin can lead to better patient compliance and lesser hypersensitivity reactions to these regimens.

**REFERENCES:**

10. ELOXATIN Prescribing information. [http://products.sano-faventius.us/Eloxatin/exloatin.html]